Epidemiology of rheumatic diseases
- PMID: 11276800
- DOI: 10.1093/rheumatology/39.suppl_2.3
Epidemiology of rheumatic diseases
Abstract
Rheumatic diseases are among the oldest diseases recognized. The classification of rheumatic diseases is sometimes difficult due to unknown aetiology and heterogeneity in their clinical presentation. Osteoarthritis (OA) and rheumatoid arthritis (RA) are the two most common rheumatic diseases, accounting for a large percentage of disability worldwide. The economic and social burden of these diseases is great. Their impact on both individuals and society results from a decreased quality of life, lost productivity and increased costs of health care. Without appropriate approaches to patient management and control of these diseases, this impact can be expected to increase as the population ages. One of the challenges in studying OA and RA, and rheumatic diseases in general, is deriving epidemiological data that can be used to understand better the factors that contribute to the initiation and progression of these diseases. Only with such an understanding can significant progress be made in the diagnosis, treatment and management of patients.
Similar articles
-
Health related quality of life in rheumatoid arthritis, osteoarthritis, diabetes mellitus, end stage renal disease and geriatric subjects. Experience from a General Hospital in Mexico.Reumatol Clin. 2015 Mar-Apr;11(2):68-72. doi: 10.1016/j.reuma.2014.03.006. Epub 2014 May 9. Reumatol Clin. 2015. PMID: 24816341 English, Spanish.
-
Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis.Arthritis Res. 2002;4(5):R5. doi: 10.1186/ar428. Epub 2002 Jun 19. Arthritis Res. 2002. PMID: 12223108 Free PMC article.
-
Evaluation of quality of life in chronic, progressing rheumatic diseases based on the example of osteoarthritis and rheumatoid arthritis.Clin Interv Aging. 2016 Nov 28;11:1741-1750. doi: 10.2147/CIA.S116185. eCollection 2016. Clin Interv Aging. 2016. PMID: 27932870 Free PMC article.
-
Update on the epidemiology of the rheumatic diseases.Curr Opin Rheumatol. 1997 Mar;9(2):90-4. doi: 10.1097/00002281-199703000-00002. Curr Opin Rheumatol. 1997. PMID: 9135910 Review. No abstract available.
-
Osteoarthritis and its management - Epidemiology, nutritional aspects and environmental factors.Autoimmun Rev. 2018 Nov;17(11):1097-1104. doi: 10.1016/j.autrev.2018.06.002. Epub 2018 Sep 11. Autoimmun Rev. 2018. PMID: 30213694 Review.
Cited by
-
A systematic review on time trend incidence of rheumatoid arthritis in outpatient rheumatology clinics.Front Med (Lausanne). 2022 Aug 24;9:933884. doi: 10.3389/fmed.2022.933884. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36091689 Free PMC article.
-
Efficient gene-environment interaction testing through bootstrap aggregating.Sci Rep. 2023 Jan 17;13(1):937. doi: 10.1038/s41598-023-28172-4. Sci Rep. 2023. PMID: 36650248 Free PMC article.
-
Evaluation of the Usefulness of Human Adipose-Derived Stem Cell Spheroids Formed Using SphereRing® and the Lethal Damage Sensitivity to Synovial Fluid In Vitro.Cells. 2022 Jan 20;11(3):337. doi: 10.3390/cells11030337. Cells. 2022. PMID: 35159147 Free PMC article.
-
Future perspectives of Smartphone applications for rheumatic diseases self-management.Rheumatol Int. 2015 Mar;35(3):419-31. doi: 10.1007/s00296-014-3117-9. Epub 2014 Aug 29. Rheumatol Int. 2015. PMID: 25168866 Review.
-
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.Ann Rheum Dis. 2003 Dec;62(12):1168-77. doi: 10.1136/ard.2003.009563. Ann Rheum Dis. 2003. PMID: 14644854 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical